Theodoros Foukakis
0000-0001-8952-9987
Publication & Citation Trends
Publications
0 total
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Cited by 1
Semantic Scholar
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study OA
Cited by 4
Semantic Scholar
Abstract PS12-09: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk, early-stage triple-negative breast cancer: Overall survival and subgroup results from the phase 3 KEYNOTE-522 study
Cited by 0
Semantic Scholar
Abstract LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
Cited by 10
Semantic Scholar
Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study
Cited by 5
Semantic Scholar
P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
Cited by 2
Semantic Scholar
LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study OA
Cited by 43
Semantic Scholar
338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study OA
Cited by 3
Semantic Scholar
Research Topics
Breast Cancer Treatment Studies
(142)
HER2/EGFR in Cancer Research
(76)
Cancer Genomics and Diagnostics
(55)
Cancer Treatment and Pharmacology
(47)
Advanced Breast Cancer Therapies
(47)
Affiliations
Ulsan College
Uppsala University
Karolinska University Hospital
University of Melbourne
Yonsei University